NCT03238027View on ClinicalTrials.gov

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

November 20, 2020

Study Completion Date

November 20, 2020

Conditions
Solid TumorMetastatic TumorLocally Advanced Malignant NeoplasmUnresectable Malignant Neoplasm
Interventions
DRUG

Axatilimab

Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)

DRUG

Durvalumab

Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules

Trial Locations (5)

21287

Johns Hopkins University, Baltimore

78229

NEXT Oncology, San Antonio

South Texas Accelerated Research Therapeutics, San Antonio

85258

Honor Health, Scottsdale

97239

Oregon Health and Science University, Portland

Sponsors
All Listed Sponsors
lead

Syndax Pharmaceuticals

INDUSTRY